Final adult height in children with congenital adrenal hyperplasia treated with growth hormone

Journal of Clinical Endocrinology and Metabolism

Volumn 96, Issue 6, 2011, Pages 1710-1717

  Lin Su, Karen ^a   Harbison, Madeleine D ^b   Lekarev, Oksana ^b   Vogiatzi, Maria G ^a   New, Maria I ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN GROWTH HORMONE; LEUPRORELIN;

ARTICLE; BODY HEIGHT; BRAIN PSEUDOTUMOR; CARPAL TUNNEL SYNDROME; CHILD; CLINICAL ARTICLE; CONGENITAL ADRENAL HYPERPLASIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG DOSE INCREASE; DRUG WITHDRAWAL; FEMALE; HUMAN; MALE; MALIGNANT NEOPLASTIC DISEASE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCHOOL CHILD; SLIPPED CAPITAL FEMORAL EPIPHYSIS; TREATMENT DURATION; UNITED STATES; UNIVERSITY HOSPITAL; WEIGHT GAIN;

ADOLESCENT; ADRENAL HYPERPLASIA, CONGENITAL; ADULT; BODY HEIGHT; CHILD; FEMALE; GONADOTROPIN-RELEASING HORMONE; HUMAN GROWTH HORMONE; HUMANS; MALE; PATIENT SELECTION; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 79956300202     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2010-2699     Document Type: Article

References (45)

1. New MI, Gertner JM, Speiser PW, Del Balzo P 1989. Growth and final height in classical and nonclassical 21-hydroxylase deficiency. J Endocrinol Invest 12(Suppl 3):91-95 (Pubitemid 19258815)
2. Blizzard R 1999 Adult consequences of pediatric endocrine disease: congenital adrenal hyperplasia. Growth Genet Horm 15:35-41
3. Cabrera MS, Vogiatzi MG, New MI 2001 Long term outcome in adult males with classic congenital adrenal hyperplasia. J Clin Endocrinol Metab 86:3070-3078 (Pubitemid 32673467)
4. White PC, Speiser PW 2000 Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Endocr Rev 21:245-291 (Pubitemid 32275589)
5. Jááskeläinen J, Voutilainen R 1997 Growth of patients with 21-hydroxylase deficiency: an analysis of the factors influencing adult height. Pediatr Res 41:30-33 (Pubitemid 27008632)
6. Klingensmith GJ, Garcia SC, Jones HW, Migeon CJ, Blizzard RM 1977 Glucocorticoid treatment of girls with congenital adrenal hyperplasia: effects on height, sexual maturation, and fertility. J Pediatr 90:996-1004
7. New MI, Gertner JM, Speiser PW, del Balzo P 1988 Growth and final height in classical and nonclassical 21-hydroxylase deficiency. Acta Paediatr Jpn 30:79-88 (Pubitemid 19047992)
8. Young MC, Ribeiro J, Hughes IA 1989 Growth and body proportions in congenital adrenal hyperplasia. Arch Dis Child 64:1554-1558 (Pubitemid 19266061)
9. David M, Sempé M, Blanc M, Nicolino M, Forest MG, Morel Y 1994 Final height in 69 patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Arch Pediatr 1:363-367 (Pubitemid 24128805)
10. Lim YJ, Batch JA, Warne GL 1995 Adrenal 21-hydroxylase deficiency in childhood: 25 years' experience. J Paediatr Child Health 31:222-227
11. Girgis R, Winter JS 1997 The effects of glucocorticoid replacement therapy on growth, bone mineral density, and bone turnover markers in children with congenital adrenal hyperplasia. J Clin Endocrinol Metab 82:3926-3929 (Pubitemid 27525488)
12. Hauffa BP, Winter A, Stolecke H 1997 Treatment and disease effects on short-term growth and adult height in children and adolescents with 21-hydroxylase deficiency. Klin Padiatr 209:71-77 (Pubitemid 27191368)
13. Brunelli V, Russo g, Bertelloni S, Gargantin L, Balducci R, Chiesa L, Livieri C, Sanctis CD, Einaudi S, Virdis R, Saggese G, Chiumello G 2003 Final height in congenital adrenal hyperplasia due to 21-hydroxylase deficiency: the Italian experience. J Pediatr Endocrinol Metab 16(Suppl 2):277-283
14. 2003 CYP21 genotype, adult height and pubertal development in 55 patients treated for 21-hydroxylase deficiency. J Clin Endocrinol Metab 88:5680-5688
15. Di Martino-Nardi J, Stoner E, O'Connell A, New MI 1986 The effect of treatment of final height in classical congenital adrenal hyperplasia (CAH). Acta Endocrinol Suppl 279:305-314 (Pubitemid 17170014)
16. Quintos JB, Vogiatzi MG, Harbison MD, New MI 2001 Growth hormone therapy alone or in combination with gonadotropin-releasing hormone analog therapy to improve the height deficit in children with congenital adrenal hyperplasia. J Clin Endocrinol Metab 86:1511-1517 (Pubitemid 32374896)
17. Tanae A, Hibi I 1988 Unresolved problems in the treatment of congenital adrenal hyperplasia. Acta Paediatr Jpn 30(Suppl):93-98 (Pubitemid 19047994)
18. Yu AC, Grant DB 1995 Adult height in women with early-treated congenital adrenal hyperplasia (21-hydroxylase type): relation to body mass index in earlier childhood. Acta Paediatr 84:899-903
19. van der Kamp HJ, Slijper FM, Brandenburg H, de Muink Keizer-Schrama SM, Drop SL, Molenaar JC 1992 Evaluation of young women with congenital adrenal hyperplasia: a pilot study. Horm Res 37(Suppl 3):45-49
20. Kaufmann S, Jones KL, Wehrenberg WB, Culler FL 1988 Inhibition by prednisone of growth hormone (GH) response to GH-releasing hormone in normal men. J Clin Endocrinol Metab 67:1258-1261 (Pubitemid 19012962)
21. Pinto G, Tardy V, Trivin C, Thalassinos C, Lortat-Jacob S, Nihoul-Fékété C, Morel Y, Brauner R 2003 Follow-up of 68 children with congenital adrenal hyperplasia due to 21-hydroxylase deficiency: relevance of genotype for management. J Clin Endocrinol Metab 88:2624-2633 (Pubitemid 36724435)
22. Manoli I, Kanaka-Gantenbein C, Voutetakis A, Manianti-Christidi M, Dacou-Voutetakis C 2002 Early growth, pubertal development, body mass index and final height of patients with congenital adrenal hyperplasia: factors influencing the outcome. Clin Endocrinol (Oxf) 57:669-676 (Pubitemid 35316986)
23. Tanner JM, Whitehouse RH, Marshall WA, Carter BS 1975 Prediction of adult height from height, bone age, and occurrence of menarche, at ages 4 to 16 with allowance for midparent height. Arch Dis Child 50:14-26
24. Tanner JM, Goldstein H, Whitehouse RH 1970 Standards for children's height at ages 2-9 years allowing for heights of parents. Arch Dis Child 45:755-762
25. Trinh L, Nimkarn S, New MI, Lin-Su K 2007 Growth and pubertal characteristics in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Pediatr Endocrinol Metab 20:883-891 (Pubitemid 47455348)
26. Hargitai G, Sólyom J, Battelino T, Lebl J, Pribilincová Z, Hauspie R, Kovács J, Waldhauser F, Frisch H 2001 Growth patterns and final height in congenital adrenal hyperplasia due to classical 21-hydroxylase deficiency. Results of a multicenter study. Horm Res 55:161-171 (Pubitemid 34701718)
27. Eugster EA, Dimeglio LA, Wright JC, Freidenberg GR, Seshadri R, Pescovitz OH 2001 Height outcome in congenital adrenal hyperplasia caused by 21-hydroxylase deficiency: a meta-analysis. J Pediatr 138:26-32 (Pubitemid 32097137)
28. Muthusamy K, Elamin MB, Smushkin G, Murad MH, Lampropulos JF, Elamin KB, Abu Elnour NO, Gallegos-Orozco JF, Fatourechi MM, Agrwal N, Lane MA, Albuquerque FN, Erwin PJ, Montori VM 2010 Adult height in patients with congenital adrenal hyperplasia: a systematic review and metaanalysis. J Clin Endocrinol Metab 95:4161-4172
29. Dacou-Voutetakis C, Karidis N 1993 Congenital adrenal hyperplasia complicated by central precocious puberty: treatment with LHRH-agonist analogue. Ann NY Acad Sci 687:250-254 (Pubitemid 23217944)
30. Pescovitz OH, Comite F, Cassorla F, Dwyer AJ, Poth MA, Sperling MA, Hench K, McNemar A, Skerda M, Loriaux DL 1984 True precocious puberty complicating congenital adrenal hyperplasia: treatment with a luteinizing hormone-releasing hormone analog. J Clin Endocrinol Metab 58:857-861 (Pubitemid 14102108)
31. Touati G, Prieur AM, Ruiz JC, Noel M, Czernichow P 1998 Beneficial effects of one-year growth hormone administration to children with juvenile chronic arthritis on chronic steroid therapy. I. Effects on growth velocity and body composition. J Clin Endocrinol Metab [Erratum (1998) 83:1547] 83:403-409 (Pubitemid 28496513)
32. New MI 2001 Factors determining final height in congenital adrenal hyperplasia. J Pediatr Endocrinol Metab 14(Suppl 2):933-937 (Pubitemid 32755367)
33. Merke DP, Bornstein SR, Avila NA, Chrousos GP 2002 NIH conference. Future directions in the study and management of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Ann Intern Med 136:320-334
34. Unterman TG, Phillips LS 1985 Glucocorticoid effects on somatomedins and somatomedin inhibitors. J Clin Endocrinol Metab 61:618-626 (Pubitemid 16248080)
35. Massart F, Federico G, Harrell JC, Saggese G 2009 Growth outcome during GnRH agonist treatments for slowly progressive central precocious puberty. Neuroendocrinology 90:307-314
36. Allen DB, Julius JR, Breen TJ, Attie KM 1998 Treatment of glucocorticoid-induced growth suppression with growth hormone. National Cooperative Growth Study. J Clin Endocrinol Metab 83:2824-2829 (Pubitemid 28493783)
37. Kohn B, Julius JR, Blethen SL 1999 Combined use of growth hormone and gonadotropin-releasing hormone analogues: the national cooperative growth study experience. Pediatrics 104(4 Pt 2):1014-1018
38. Pucarelli I, Segni M, Ortore M, Moretti A, Iannaccone R, Pasquino AM 2000 Combined therapy with GnRH analog plus growth hormone in central precocious puberty. J Pediatr Endocrinol Metab 13(Suppl 1):811-820
39. Volta C, Regazzi C, Ndaka J, Vitale R, Bernasconi S 2005 Combined therapy with luteinizing hormone releasing hormone agonist (LHRHa) and growth hormone (GH) in central precocious puberty. Acta Biomed 76:73-78
40. Lin-Su K, Vogiatzi MG, Marshall I, Harbison MD, Macapagal MC, Betensky B, Tansil S, New MI 2005 Treatment with growth hormone and luteinizing hormone releasing hormone analog improves final adult height in children with congenital adrenal hyperplasia. J Clin Endocrinol Metab 90:3318-3325 (Pubitemid 41014292)
41. Bayley N, Pinneau SR 1952 Tables for predicting adult height from skeletal age: revised for use with the Greulich-Pyle hand standards. J Pediatr 40:423-441
42. Greulich W, Pyle S 1959 Radiographic atlas of skeletal development of the hand and wrist. 2nd ed. Stanford, CA: Stanford University Press
43. New MI 2006 Extensive clinical experience: nonclassical 21-hydroxylase deficiency. J Clin Endocrinol Metab 91:4205-4214 (Pubitemid 44833386)
44. Speiser PW, Dupont B, Rubinstein P, Piazza A, Kastelan A, New MI 1985 High frequency of nonclassical steroid 21-hydroxylase deficiency. Am J Hum Genet 37:650-667 (Pubitemid 16249426)
45. Speiser PW, Azziz R, Baskin LS, Ghizzoni L, Hensle TW, Merke DP, Meyer-Bahlburg HF, Miller WL, Montori VM, Oberfield SE, Ritzen M, White PC 2010 Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 95:4133-4160